Mental health diagnosis has always had a measurement problem. Unlike cardiology or oncology, psychiatry has historically relied on self-reported symptoms and clinical observation rather than objective biological markers. A new agreement between SAKINA, the mental health network operating under SEHA and PureHealth, and US-based medical technology company PeakLogic suggests that may be starting to change, at least in the UAE.
The two organizations have signed a Memorandum of Understanding to explore advanced neuroscience tools for the diagnosis and treatment of mental and brain health conditions. The partnership is early-stage, but it signals a clear strategic direction: moving psychiatric assessment closer to the model used in the rest of medicine, where data informs decisions.
How will it work?
PeakLogic’s platform centers on neuroimaging and quantitative EEG analysis, which measures electrical activity patterns in the brain. These tools can generate objective data points about brain function that clinicians can use alongside traditional psychiatric evaluation. The MOU sets out a framework to explore how these technologies could be integrated into SAKINA’s clinical services across the UAE. That includes potential applications in:
- Diagnosing conditions such as depression, anxiety, PTSD, and traumatic brain injury
- Guiding medication selection based on neurological response patterns
- Tracking treatment outcomes over time using measurable brain activity data
- Supporting clinical training and research capacity within SEHA’s network
The goal is not to replace clinicians. It’s to give them better information.
Why does it matter?
The UAE has invested significantly in expanding mental health infrastructure over the past decade, and SAKINA is a central part of that effort. But access to care is only part of the equation. The quality and precision of that care also matter. Psychiatry, practiced without objective measurement, depends heavily on clinician experience and patient self-report, both of which introduce variability. If brain-based diagnostics can reduce that variability, even partially, the clinical benefit could be meaningful. Better-targeted treatment means faster recovery, fewer failed medication trials, and lower long-term burden on both patients and health systems.
The context
PeakLogic has worked with military and veteran health systems in the United States, where brain injury and PTSD are significant clinical priorities. That experience gives them a reasonably well-documented track record in high-stakes psychiatric settings. Still, translating a technology from one healthcare system to another is never straightforward. Regulatory pathways, clinical workflows, and patient populations all differ. This MOU is an exploratory step, not a deployment announcement. The real test will come when pilot data emerges and the two organizations decide whether the tools perform as expected in a UAE clinical context. But the direction is credible. Neuroscience-informed psychiatry is gaining ground globally, and this partnership puts the UAE’s largest public health network in a position to learn from it early.